While it has been suggested that JC virus (JCV) migrates in B-lymphocytes from the kidney to the central nervous system where it initiates demyelination, this phase of JCV pathogenesis has not been systematically explored. To determine the peripheral blood cell subpopulation(s) infected with JCV, monocytes, granulocytes, and T and B lymphocytes from HIV-1-infected individuals and uninfected controls were puri®ed by¯ow cytometry. JCV DNA could be detected by PCR ampli®cation in all of these cell subpopulations. This ®nding suggests that JCV lacks speci®city in its interaction with leukocytes.
The mechanism by which JC virus (JCV) induces the demyelinating disease progressive multifocal leukoencephalopathy (PML) in immunosuppressed individuals remains unclear. Asymptomatic JCV infection occurs in 70 ± 90% of normal persons (Walker and Padgett, 1983) . JCV remains latent in the kidney, and is intermittently shed in the urine (Arthur et al, 1989; Kitamura et al, 1990; Markowitz et al, 1993; Koralnik et al, 1999) . In the setting of immunosuppression, JCV can be detected in peripheral blood mononuclear cells (PBMC) and plasma Azzi et al, 1996; Dubois et al, 1996 Dubois et al, , 1997 Ferrante et al, 1997; Koralnik et al, 1999) . It has been suggested that JCV may enter the central nervous system (CNS) in infected peripheral blood cells Gallia et al, 1997) .
JCV has been detected in two individuals with PML in bone marrow lymphocytes bearing kappa light chains (Houff et al, 1988) , in one in CD45R positive cells in the brain (Major et al, 1990) and in another in peripheral blood B-lymphocytes (Monaco et al, 1996) . Between 1 and 5.9% of cells from transformed B-lymphocyte lines (Atwood et al, 1992) , hematopoietic progenitor cell lines and primary tonsilar B-lymphocytes have been infected in vitro with JCV (Monaco et al, 1996) . This virus has also been detected in B-lymphocyte-depleted peripheral blood leukocytes of HIV-infected individuals (Dubois et al, 1997) and in brain macrophages of patients with PML (Orenstein et al, 1988; Stoner et al, 1986; Boldorini et al, 1993) . Finally, JCV has been found in cell-free plasma of immunosuppressed individuals (Dubois et al, 1997 (Dubois et al, , 1998 Koralnik et al, 1999) . These disparate observations do not provide a coherent picture of how JCV might be transported from the kidney into the CNS to initiate demyelinating disease. To clarify the mechanisms of JCV latency and spread, we have characterized the peripheral blood cells that harbor JCV in HIV-1-infected individuals.
JCV detection after double gradient separation of PBMC and granulocytes EDTA-anticoagulated peripheral blood from HIV-1-infected individuals and uninfected control subjects was diluted 1 : 1 in PBS, and centrifuged for 30 min at 7006g on a double gradient column consisting of a layer of Histopaque and a layer of Ficoll-diatrizoate. PBMC and granulocytes were recovered at the plasma/Ficoll interface and the Histopaque/Ficoll interface, respectively. Remaining red blood cells were eliminated by incubation in erythrocyte lysis buffer for 3 min. The purity of the PBMC and granulocyte populations were determined by¯ow cytometry (Figure 1 ). DNA was extracted from these cell populations and from plasma samples as previously described (Koralnik et al, 1999) . In brief, cells were lysed by addition of SDS in the presence of proteinase K. DNA was extracted with phenol/chloroform/isoamyl alcohol and precipitated with ethanol. Plasma samples were centrifugated twice at 2000 r.p.m. for 5 min and ®ltered through 0.45 m ®lters to remove remaining cells. Viral particles were pelleted by centrifugation at 214 0006g, and DNA was extracted as described above.
PCR ampli®cation of JCV DNA and detection of the ampli®ed products was performed as previously described (Koralnik et al, 1999) using the primer pair VP11/VP12 which¯anks a 181 bp fragment of the VP1 gene (Gibson et al, 1993) . The PCR oligonucleotide primer sequences employed are: VP11: 5'-cagatacatttgaaagtgac-3' (nt 1662 ± 1681); VP12: 5'-ccattagagtgcacattcatc-3' (nt 1842 ± 1822).
The ampli®cation was carried out using 40 reaction cycles. 0.5 ± 1.0 mg of PBMC or granulocytes DNA, or DNA extracted from 6 ml of plasma were used in a 50 ml reaction consisting of 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl 2 , 200 mM of each dNTP, 2.5 U Amplitaq DNA polymerase (Perkin Elmer, Cetus), and 25 pmol of each oligonucleotide primer pair. Twenty ®ve ml of the PCR reaction was analyzed by electrophoresis on a 2% agarose gel, transferred onto nylon membranes by Southern blotting, and ampli®ed products were detected by hybridization to the JCV speci®c 32 P end-labelled oligonucleotide probe IKVP1S. The IKVP1S oligonucleotide probe sequence employed is: 5'-ggacatgcttccttgttacagtgtg-3' (nt 1693 ± 1717). A positive control JCV VP1 gene fragment was generated as previously described (Koralnik et al, 1999) . Using these conditions, we could reliably detect as few as ten copies of JCV DNA.
Samples were evaluated from 48 individuals, including 5 HIV+/PML+ cases, 25 HIV+/PML7 cases, 2 HIV7/PML+ cases, 2 HIV7/PML7 immunosuppressed cases, and 14 HIV7/PML7 normal control subjects. Among these, only three HIV+/PML+ patients and 5 HIV+/PML7 patients had detectable JCV DNA in PBMC or granulocytes. The enrichment of the PBMC and granulocyte populations was 75 ± 99% (average 87%) ( Table 1) .
As shown in Table 1 , JCV DNA could be detected in 6/8 PBMC and 3/8 granulocyte cell populations. Plasma samples were positive for JCV DNA in 3/6 cases tested. Only one individual was positive for JCV DNA in both PBMC and granulocytes. This patient had PML, and had detectable JCV DNA in the plasma as well. These results indicate that JCV can be associated with either the PBMC or the granulocyte cell population in HIV-infected individuals.
JCV detection in sorted peripheral blood cell subpopulations To characterize further the cells carrying JCV in the blood, T lymphocyte, B lymphocyte, monocyte and granulocyte cell populations were isolated by¯ow cytometric sorting. Samples were evaluated from HIV-1 seropositive subjects who had PML (four cases), or advanced AIDS with CD4 counts of less than 250/ml (six cases), and uninfected control subjects (three cases). These individuals were different from those reported in Table 1 , except for case three. After double gradient centrifugation, the intermediate+ (granulocytes). The combination of two different mAb directed against CD14 and CD16 was used to include all subsets of monocytes (Thieblemont et al, 1995) . Figure 2 shows an example of the degree of enrichment of blood cell populations that could be achieved using specimens obtained from both HIV-1-infected and uninfected control subjects.
As shown in Figure 2 , the enrichment of blood cell subpopulations was more successful in specimens from HIV-control subjects (98.2 ± 99.9%) than in specimens from HIV+ individuals (91.4 ± 99.9%). The less ef®cient cell puri®cation from specimens obtained from HIV-infected individuals may be attributable to the fragility of these activated cells in individuals with end stage AIDS. This fragility may lead to increased cell clumping. DNA from enriched cell subpopulations was extracted and PCR ampli®cation of JCV DNA was performed as described above. The results of the JCV PCR ampli®cations on DNA specimens obtained from ten HIV+ and three HIV7 control subjects are shown in Table 2 .
JCV DNA was detected in 2/13 T-lymphocyte, 2/ 13 B-lymphocyte, 1/8 granulocyte and 2/12 monocyte enriched cell fractions of peripheral blood (Figure 3) . It was also detected in 2/12 plasma samples (Figure 3) .
In HIV-1-seronegative control subjects, JCV DNA was detected only in the B cell fraction of one individual (case 11). One HIV+ individual (case 7) had detectable JCV DNA only in the plasma. JCV DNA could not be detected in the unsorted or sorted cell populations of one HIV+/PML+ patient (case 4), four HIV+/PML7 patients (cases 7 ± 10) and two uninfected control subjects (cases 12 and 13). No association was observed between the cell populations that were positive for JCV DNA and the diagnosis of PML in this group of HIV+ patients.
At least one cell population in the blood specimens from three of four HIV-infected patients with PML yielded a positive PCR signal for JCV DNA. These positive PCR signals were detected in specimens from two of three HIV+/PML7 individuals with CD4 counts between eight and 71/ml, 0/3 HIV+ individuals with CD4 counts between 168 and 223/ ml, and 1/3 HIV negative control subjects. These ®ndings are consistent with the observation that the frequency of detection of JCV in the blood increases in the setting of advanced immunosuppression (Koralnik et al, 1999) .
Interestingly, unsorted PBMC or granulocyte populations from three HIV+ and one HIV7 individual were PCR negative for JCV DNA while T cells (cases 3 and 6), monocytes (case 5), granulocytes (case 6) and B cells (case 11) enriched from the same cell populations had detectable JCV DNA. Case 3 is the only patient shown in Table 2 who had been evaluated 22 months previously for the presence of JCV DNA in the PBMC and granulocytes using the double gradient separation technique (case 3, Table 1 ). At that time, this HIV+/ PML+ patient was PCR positive for JCV in the PBMC. His brain lesions and his neurological impairment had already improved on highly active antiretroviral therapy (HAART) when the cell sorting analyses were performed on his PBMC and granulocytes. Only his puri®ed T cell fraction was positive for JCV DNA (Table 2, Figure 3) .
These ®ndings suggest that cell-associated JCV may be present in limiting amounts in the peripheral blood of these individuals, and that enrichment of speci®c cell populations carrying the virus is necessary to reach the threshold of detection of the PCR-based assay. This explanation is consistent with our recent ®nding that JCV DNA is detected in PBMC in limited amounts using quantitative PCR, between 10 and 90 copies/mg PBMC DNA (Koralnik et al, 1999) . 
a +: positive detection of JCV VP1 gene DNA after PCR ampli®cation, Southern blot and hybridization with a 32 Plabeled JCV-speci®c probe as indicated in the text.
b NA: specimen not available. In the same study, we were unable to detect JCV DNA in any of 18 PBMC and 13 plasma samples from HIV7 control subjects. The observation that we were able to detect JCV DNA in the puri®ed Blymphocyte peripheral blood fraction but not in the unsorted PBMC of one HIV7 control (case 11) suggests that JCV viremia may occur at very low levels in immunocompetent individuals (Dorries et al, 1994) . This individual was PCR negative for JCV DNA in all blood cell subpopulations on repeat testing 1 month after the evaluation shown in Table  2 and Figure 3 (data not shown) .
These data con®rm and extend the results of previous studies in which JCV was detected in peripheral blood B-lymphocytes (Monaco et al, 1996) , as well as in B-lymphocyte-depleted peripheral blood leukocytes of HIV-1-infected individuals (Dubois et al, 1997) . The fact that JCV DNA was not found exclusively in a single peripheral blood cell type raises questions about the presumed speci®city of the association between JCV and B lymphocytes. Because of the extreme sensitivity of the PCR technique and the limits in the purity of cell subpopulations that could be achieved after¯ow cytometric sorting, it is possible that JCV might have been detected in our sorted samples in limited numbers of contaminating cells from other leukocyte subpopulations. This is unlikely, since JCV DNA was detected in a single cell type in four instances (cases 1, 3, 5, 11), and JCV DNA was found in two different cell types in two cases (cases 2 and 6). Our data, therefore, did not demonstrate a preferential association of JCV with a particular peripheral blood cell subpopulation.
The receptor for JCV on blood cells is still unknown. In fact, it is possible that the cellassociated JCV DNA detected in the present study came from viral particles sticking nonspeci®cally to the surface of cells, and not from productively infected blood cells. Indeed, JCV seems to be present in blood during viral latency since JCV RNA, an indicator of active viral replication, was found in the blood of only 1/72 HIV-infected individuals in a recent study (Dubois et al, 1997) . JC viremia, occurring in the setting of immunosuppression, is a likely mechanism of viral spread to the CNS. However, JCV in the blood appears to be carried by a variety of leukocyte subpopulations as well as in the plasma. Further studies are needed to establish the nature of the interaction of JCV and peripheral blood leukocytes in vivo.
